Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096097 | 0.93 | P2RY12 (0.46) | P2RY12 | |
| SCHEMBL1096415 | 0.86 | P2RY12 (0.37) | CXCR3P2RY12MAPTCYP2C9CYP2C19 | |
| SCHEMBL1096517 | 0.82 | ACACB (0.43) | CXCR3ACACBP2RY12CCR5 | |
| Hydrochloric Acid SCHEMBL1096096 | 0.81 | ACACB (0.42) | CXCR3ACACBP2RY12CCR5 | |
| SCHEMBL1095805 | 0.80 | P2RY12 (0.47) | P2RY12 | |
| SCHEMBL1105934 | 0.79 | CCR5 (0.41) | HSD17B2CCR5TRPM8FFAR1 | |
| SCHEMBL1097649 | 0.78 | P2RY12 (0.35) | CXCR3P2RY12MAPTCYP2C9CYP2C19 | |
| SCHEMBL1095567 | 0.78 | CASR (0.36) | ACACBCCR5TRPM8 | |
| SCHEMBL1096138 | 0.75 | TRPM8 (0.42) | HSD17B2TRPM8MAPTFFAR1 | |
| SCHEMBL1096777 | 0.74 | DGAT2 (0.35) | ACACBCCR5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2085383-A1 | PIPERIDINE DERIVATIVES OR SALTS THEREOF | Astellas Pharma Inc. (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | CXCR3 2808/4885ACACB 4469/4885P2RY12 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.